Morgan Stanley Greenwich Life Sciences, Inc. Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLSI
# of Institutions
38Shares Held
1.1MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY309KShares$3.88 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA274KShares$3.44 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA134KShares$1.68 Million0.0% of portfolio
-
Credit Agricole S A87KShares$1.09 Million0.01% of portfolio
-
Northern Trust Corp Chicago, IL74.5KShares$935,7200.0% of portfolio
About Greenwich LifeSciences, Inc.
- Ticker GLSI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,848,200
- Market Cap $161M
- Description
- Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...